Silencing of integrin-linked kinase suppresses in vivo tumorigenesis of human ovarian carcinoma cells

Li,Qi; Li,Chen; Zhang,Yun-Yan; Chen,Wei; Lv,Jun-Li; Sun,Jing; You,Qing-Shan

doi:10.3892/mmr.2013.1285

Silencing of integrin-linked kinase suppresses in vivo tumorigenesis of human ovarian carcinoma cells

Authors:
- Qi Li
- Chen Li
- Yun-Yan Zhang
- Wei Chen
- Jun-Li Lv
- Jing Sun
- Qing-Shan You
View Affiliations

Affiliations: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang, P.R. China, Department of Dermatology, Heilongjiang Provincial Hospital, Harbin 150036, Heilongjiang, P.R. China
Published online on: January 22, 2013 https://doi.org/10.3892/mmr.2013.1285
Pages: 1050-1054

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Integrin-linked kinase (ILK) plays a role in the regulation of multiple cellular functions (e.g., promoting cell migration and proliferation, but inhibiting cell adhesion). This study investigated the inhibitory effects of ILK gene knockdown on the regulation of in vivo tumorigenesis of human ovarian carcinoma cells in nude mouse xenografts. HO-8910 cells were transfected with an ILK antisense oligonucleotide (ILK-ASO) to silence the ILK gene. Expression of ILK mRNA and protein was evaluated by RT-PCR and western blotting, respectively. The cell cycle was assessed by flow cytometric analysis. Cells with or without ILK-ASO transfection were subcutaneously injected into nude mice. The mouse body weight, tumor formation, tumor size and tumor weight were determined up to 30 days after inoculation. Tumor cells transfected with ILK-ASO had significantly decreased ILK mRNA and protein expression (P<0.01) when compared to the control cells. ILK gene silencing significantly increased the number of cells in the G0/G1 phase (67.61 vs. 43.29%, χ2=1197.15, P<0.01). After tumor cell inoculation, tumor cells transfected with ILK-ASO showed significantly delayed tumor formation when compared to control (9.10±0.74 vs. 5.30±0.67 days, respectively; P<0.01). In addition, tumor growth was suppressed in the 30 days following inoculation (P<0.01 compared with the controls). The average tumor weight in the ILK-ASO group was statistically lower than that of the control group (1.29±0.11 vs. 1.57±0.13 g, respectively; P<0.01). This study demonstrated that ILK-ASO transfection efficiently downregulated ILK expression in human ovarian carcinoma HO-8910 cells and that ILK gene silencing suppressed tumor growth in nude mice xenografts.

View Figures

View References

1	Notani P: Global variation in cancer incidence and mortality. Curr Sci. 81:465–475. 2001.
2	Holschneider CH and Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
3	Cannistra SA, Ottensmeier C, Niloff J, Orta B and DiCarlo J: Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol. 58:216–225. 1995. View Article : Google Scholar : PubMed/NCBI
4	Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C and Dedhar S: alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene. 22:1688–1702. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ruseva Z, Geiger PX, Hutzler P, Kotzsch M, Luber B, Schmitt M, Gross E and Reuning U: Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation. Exp Cell Res. 315:1759–1771. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK and Lengyel E: {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 175:2184–2196. 2009.
7	Mulrooney J, Foley K, Vineberg S, Barreuther M and Grabel L: Phosphorylation of the beta1 integrin cytoplasmic domain: toward an understanding of function and mechanism. Exp Cell Res. 258:332–341. 2000. View Article : Google Scholar : PubMed/NCBI
8	Dedhar S, Williams B and Hannigan G: Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol. 9:319–323. 1999. View Article : Google Scholar : PubMed/NCBI
9	McDonald PC, Fielding AB and Dedhar S: Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci. 121:3121–3132. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ahmed N, Riley C, Oliva K, Stutt E, Rice GE and Quinn MA: Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol. 201:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
11	Gao J, Zhu J, Li HY, Pan XY, Jiang R and Chen JX: Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder cancer cells. Int J Biochem Cell Biol. 43:1294–1304. 2011. View Article : Google Scholar : PubMed/NCBI
12	Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, et al: Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene. 29:3374–3385. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chan J, Ko FC, Yeung YS, Ng IO and Yam JW: Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One. 6:e169842011. View Article : Google Scholar : PubMed/NCBI
14	Liu Q, Xiao L, Yuan D, Shi X and Li P: Silencing of the integrin-linked kinase gene induces the apoptosis in ovarian carcinoma. J Recept Signal Transduct Res. 32:120–127. 2012. View Article : Google Scholar : PubMed/NCBI
15	Hannigan G, Troussard AA and Dedhar S: Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 5:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yang Y, Fukui K, Koike T and Zheng X: Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons. Eur J Neurosci. 26:2979–2988. 2007. View Article : Google Scholar : PubMed/NCBI
17	McDonald PC and Dedhar S: The role of integrin-linked kinase in cancer development and progression. Cell-Extracellular Matrix Interactions in Cancer. Zent R and Pozzi A: Springer; New York: pp. 245–273. 2010, View Article : Google Scholar
18	Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP and Levin AA: Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci. 46:365–375. 1998.PubMed/NCBI
19	Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J and Dedhar S: Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem. 272:13937–13944. 1997. View Article : Google Scholar : PubMed/NCBI
20	Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J and Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA. 97:3207–3212. 2000. View Article : Google Scholar : PubMed/NCBI
21	Rayburn ER and Zhang R: Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today. 13:513–521. 2008. View Article : Google Scholar : PubMed/NCBI